文献速递帕金森病与运动障碍

益生菌治疗帕金森病便秘:随机安慰剂对照研究

Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study.
PubMed 文献 · Neurology · 2020-10-12

这项双盲随机安慰剂对照单中心试验筛查280例帕金森病患者,纳入72例随机分入多菌株益生菌组(n=34)或安慰剂组(n=38)治疗4周。主要终点为干预最后2周与干预前2周每周平均自发排便次数变化,益生菌组增加1.0±1.2次/周,安慰剂组减少0.3±1.0次/周(均差1.3,95%CI 0.8-1.8,p<0.001)。多菌株益生菌对帕金森病便秘有效。

要点

  • 多菌株益生菌组每周自发排便次数较安慰剂组显著增加。
  • 粪便性状和便秘相关生活质量在多重比较校正后显著改善。
  • 治疗组65.6%满意干预,安慰剂组仅21.6%(p<0.001)。

核心结论

  • 多菌株益生菌治疗对帕金森病患者的便秘有效。

研究设计与样本

  • 双盲、随机、安慰剂对照、单中心试验,筛查280例帕金森病患者,纳入72例并1:1区组随机分入多菌株益生菌组(n=34)或外观相同安慰剂组(n=38),疗程4周。

主要发现

  • 益生菌组每周自发排便次数增加1.0±1.2次,安慰剂组减少0.3±1.0次,均差1.3(95%CI 0.8-1.8,p<0.001)。
  • 多重比较校正后,粪便性状(p=0.009)和便秘相关生活质量(p=0.001)显著改善。
  • 治疗组65.6%对干预满意,安慰剂组21.6%(p<0.001)。
  • 治疗组1例(2.9%)因非严重不良事件退出。
  • 粪便钙卫蛋白在研究期间无显著变化。

关键数值与推荐

  • 主要终点为干预最后2周较干预前2周每周平均自发排便次数变化,由每日排便日记记录。

临床怎么用

  • 多菌株益生菌可考虑用于改善帕金森病患者的便秘症状。
  • 需进一步研究益生菌在帕金森病中的长期疗效、安全性及作用机制。

局限性

  • 单中心研究,样本量较小(共72例)。
  • 干预仅4周,未评估长期疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether probiotics are effective for constipation, a common and often difficult-to-treat problem, in Parkinson disease (PD). METHODS: In this double-blind, randomized, placebo-controlled, single-center trial, 280 patients with PD were screened, and 72 eligible patients were block-randomized (1:1) to receive either multistrain probiotics capsules (n = 34) or identical-appearing placebo (n = 38), for 4 weeks. The primary endpoint was the change in the average number of spontaneous bowel movements (SBM) per week during the last 2 weeks of intervention compared with the 2-week preintervention phase, recorded by daily stool diary. Secondary outcome measures included changes in stool consistency, constipation severity score, and quality of life related to constipation. Satisfaction with intervention received was assessed. Change in levels of fecal calprotectin, a marker of intestinal inflammation, was an exploratory outcome. RESULTS: SBM increased by 1.0 ± 1.2 per week after treatment with probiotics and decreased by 0.3 ± 1.0 per week in the placebo group (mean difference 1.3, 95% confidence interval 0.8-1.8, p < 0.001). Significant improvements were also seen for secondary outcomes after correction for multiple comparisons, including stool consistency (p = 0.009) and quality of life related to constipation (p = 0.001). In the treatment group, 65.6% reported satisfaction with the intervention vs only 21.6% in the placebo group (p < 0.001). One patient (2.9%) in the treatment group withdrew due to a nonserious adverse event. Fecal calprotectin did not change significantly during the study. CONCLUSIONS: Multistrain probiotics treatment was effective for constipation in PD. Further studies are needed to investigate the long-term efficacy and safety of probiotics in PD, as well as their mechanisms of action. CLINICALTRIALSGOV IDENTIFIER: NCT03377322. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that, for people with PD, multistrain probiotics significantly increased the average number of SBM per week.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Tan AH, Lim SY, Chong KK, et al. Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. Neurology. 2020. PMID: 33046607. doi:10.1212/WNL.0000000000010998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。